Cargando…
mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase
Autores principales: | Koo, Grace, Anvari, Sara, Friedman, Debra L., Zarnegar-Lumley, Sara, Szafron, Vibha, Kahwash, Basil M., Onasch, K. Michelle, Hall, Laura, Phillips, Elizabeth J., Stone, Cosby A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526431/ https://www.ncbi.nlm.nih.gov/pubmed/34678498 http://dx.doi.org/10.1016/j.jaip.2021.09.051 |
Ejemplares similares
-
Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019) -
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019) -
Pegaspargase Induced Hypertriglyceridemia Resulting in Severe Fatal Pancreatitis
por: Vyas, Neil, et al.
Publicado: (2015) -
Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014) -
Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)